A Confident Approach to EU MDR Device Classification

2026-11-03T15:08:18+00:00November 3rd, 2026|Categories: Clinical Trial, EMA, Europe, European Union, MDR, Medical Devices, Meditrial, Regulatory, Regulatory Affairs|

A device that looks similar to an existing product may still require a different EU MDR classification. Under Regulation (EU) 2017/745, medical device classification must be based on the device's intended purpose, inherent risks, and applicable classification rules, rather [...]

A Defensible 510(k) Submission Starts With the Predicate

2026-11-03T14:15:16+00:00October 28th, 2026|Categories: 510(k), Clinical Trial, FDA, Medical Devices, Meditrial, Regulatory, Regulatory Affairs, USA|

A 510(k) submission can be delayed by an unresolved predicate strategy long before the FDA reviews a single test report. If the device's intended use, technological characteristics, and evidence do not support substantial equivalence, a complete-looking dossier will not [...]

A Confident UK Device Launch Starts With Your MHRA Strategy

2026-10-22T07:59:28+00:00October 20th, 2026|Categories: Clinical Trial, Europe, Medical Devices, Meditrial, Regulatory, Regulatory Affairs, UK|

Registering a medical device with the Medicines and Healthcare products Regulatory Agency (MHRA) is necessary for Great Britain market access, but registration alone does not establish regulatory compliance. Manufacturers must also address conformity assessment, clinical evidence, representation, and post-market [...]

A Clearer Global Regulatory Strategy for Medical Device Launches

2026-10-15T09:12:26+00:00October 14th, 2026|Categories: 510(k), Clinical Trial, Europe, European Union, FDA, MDR, Medical Devices, Meditrial, Regulatory, Regulatory Affairs, Switzerland, USA|

The order in which a device enters its markets can shape cost and timeline as much as its classification does. A global regulatory strategy medical device manufacturers agree on before the first filing is where that order gets decided, [...]

PRAC Strategy on Measuring Pharmacovigilance Activities

2023-03-29T13:55:52+00:00April 22nd, 2022|Categories: Compliance, Europe, Regulatory|Tags: , , , , |

In 2017, PRAC established a strategy for measuring the impact of pharmacovigilance activities, and EMA has published a second revision in April 2022. The second revision of the PRAC Impact Strategy integrates the achievements over a five-year period since its launch in [...]

Go to Top